SCHEDULE: Paradigm BioCapital Discloses 6.2% Stake in Merus N.V.

Paradigm BioCapital Advisors LP and its affiliates have disclosed a 6.2% beneficial ownership stake in Merus N.V. common shares as of September 30, 2025.

Summary

• Paradigm BioCapital Advisors LP, along with its general partner Paradigm BioCapital Advisors GP LLC, and its managing member Senai Asefaw, M.D., collectively reported beneficial ownership of 4,673,770 common shares of Merus N.V.
• This aggregate ownership represents 6.2% of Merus N.V.'s outstanding common shares.
• The reported stake includes 4,373,770 directly held common shares and an additional 300,000 common shares underlying call options exercisable within 60 days.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 4,121,059 common shares, representing 5.4% of the class.
• The percentages are based on 75,840,942 shares outstanding as of September 30, 2025, as reported by Merus N.V. in its Form 10-Q.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of Merus N.V., except for activities related to nominations under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investment by Paradigm BioCapital in Merus N.V., which can be interpreted as a vote of confidence. However, it is a standard ownership disclosure and does not contain performance data or strategic updates from the issuer.

Positives

• A significant institutional investor, Paradigm BioCapital, has taken a substantial stake in Merus N.V., potentially signaling confidence in the company's long-term prospects.
• The disclosure of a 6.2% beneficial ownership by a specialized biotech investor could attract further institutional interest.

Risks

• The value of the investment is subject to market fluctuations and the performance of Merus N.V.'s underlying business.
• Concentration risk for Paradigm BioCapital due to a significant holding in a single issuer.
• Potential for future changes in ownership, which could impact market perception or share price.

Future Outlook

Not applicable, as this filing does not provide forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

The investment by Paradigm BioCapital, a firm specializing in biotech, suggests a strategic interest in Merus N.V.'s position within the biotechnology sector. This type of institutional investment is common in the biotech industry, where companies often rely on significant capital injections and long-term investor confidence to fund research and development.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant institutional investment as a positive signal, potentially increasing confidence and attracting further investment.
• Management: Merus N.V.'s management now has a significant institutional shareholder to consider, though the filing states no intent to influence control beyond potential nominations.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant beneficial ownership stake by Paradigm BioCapital in Merus N.V. While the acquisition of a 6.2% stake by a specialized biotech investor can be seen as a positive signal of confidence in Merus N.V.'s prospects, the filing itself does not provide new operational, financial, or strategic information about the company that would warrant a change in investment thesis. Investors should 'hold' and continue to monitor Merus N.V.'s fundamental performance and future disclosures for actionable investment decisions, as this filing alone does not provide sufficient grounds for a strong buy or sell recommendation.

Keywords

Merus N.V., Paradigm BioCapital, Schedule 13G, beneficial ownership, institutional investor, common shares, biotech, N5749R100, SEC filing